Company: SHPH
Filing Date: 2025-05-06
Form Type: DEF 14A
Source: 0001641172-25-008884
Chunk: 0

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-05-06
Form: DEF 14A
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

(Rule 14a - 101)

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934</div>

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

| ☐ | Preliminary                                                         
 Proxy Statement                                                     |
| ☐ | Confidential,                                                       
 for Use of the Commission Only (as permitted by Rule 14a - 6(e)(2)) |
| ☒ | Definitive                                                          
 Proxy Statement                                                     |
| ☐ | Definitive                                                          
 Additional Materials                                                |
| ☐ | Soliciting                                                          
 Material Pursuant to §240.14a - 12                                  |

<div align='center'>SHUTTLE PHARMACEUTICALS HOLDINGS, INC.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</div>

Payment of Filing Fee (Check all boxes that apply):

| ☒ | No                                                                                              
 fee required                                                                                    |
| ☐ | Fee                                                                                             
 paid previously with preliminary materials                                                      |
| ☐ | Fee                                                                                             
 computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a–6(i)(1) and 0–11 |

<div align='center'>Explanatory Note</div>

This additional definitive proxy statement on Schedule 14A (the “Additional Proxy Material”) is being filed for purposes of adding two additional proposals, Proposal No. 7 and Proposal No. 8, to the matters to be voted on at the 2025 Annual Meeting of Stockholders of Shuttle Pharmaceuticals Holdings, Inc. (the “Company”), scheduled to be held virtually on May 9, 2025 at 12 pm ET at www.virtualshareholdermeeting.com/SHPH2025. These additional proposals in no way invalidate the proxy statement previously mailed to all stockholders.

Therefore, this Additional Proxy Material is being filed herewith to add in Proposal No. 7, approval of an issuance in excess of 20% of the Company’s outstanding common stock at a price less than the “Minimum Price,” as defined in Nasdaq Listing Rule 5635(d), to allow the Company to seek additional funding at a 10% discount to market, which discount will